|
7. Basic and diluted income/(loss) per share
Summary of basic and diluted earnings per share
| |
|
June 30, |
|
|
June 30, |
|
| |
|
Six months ended |
|
| |
|
June 30, |
|
|
June 30, |
|
| |
|
2022 |
|
|
2021 |
|
| |
|
£ |
|
|
£ |
|
| Income/(loss) for the period |
|
|
512,658 |
|
|
|
(2,648,192 |
) |
| Basic weighted average number of shares outstanding (1) |
|
|
551,923 |
|
|
|
390,202 |
|
| Basic and diluted weighted average number of shares outstanding (1)
|
|
|
674,398 |
|
|
|
390,202 |
|
| |
|
|
|
|
|
|
|
|
| Basic income/(loss) per share |
|
|
0.93 |
|
|
|
(6.79 |
) |
| Diluted income/(loss) per share |
|
|
0.76 |
|
|
|
(6.79 |
) |
| |
(1) |
On November 18, 2022, the
Company undertook a reverse share split such that fifty issued ordinary shares were exchanged for one new share. The outstanding
shares presented above reflect the fifty for one reverse share split. |
Basic
income/(loss) per share is calculated by dividing the income/(loss) for the period attributable to the equity holders of the Group by
the weighted average number of shares outstanding during the period.
The
following potential shares, presented to reflect the fifty for one reverse share split noted above are anti-dilutive and are therefore
excluded from the weighted average number of shares for the purpose of diluted income/(loss) per share:
Schedule
of anti-dilutive weighted average shares
| |
|
2022 |
|
|
2021 |
|
| |
|
Six months ended June 30,
|
|
|
Six months ended June 30,
|
|
| |
|
2022 |
|
|
2021 |
|
| |
|
Number of shares |
|
|
Number of shares |
|
| Convertible loan notes – assuming all loan notes are converted to equity (including all warrants are fully exercised) |
|
|
33,768 |
|
|
|
- |
|
| TC BioPharm Limited Enterprise Management Incentive Plan 2014 |
|
|
- |
|
|
|
106,585 |
|
| 2021 Share Option Scheme |
|
|
52,305 |
|
|
|
- |
|
| Warrants issued at the time of the IPO |
|
|
318,443 |
|
|
|
- |
|
| Options to subscribe for ordinary shares at a future date based on certain clinical and commercial milestones |
|
|
- |
|
|
|
15,891 |
|
| Dilutive effect securities |
|
|
404,516 |
|
|
|
122,476 |
|
|